"Nitriles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
| Descriptor ID |
D009570
|
| MeSH Number(s) |
D02.626
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitriles".
Below are MeSH descriptors whose meaning is more specific than "Nitriles".
This graph shows the total number of publications written about "Nitriles" by people in this website by year, and whether "Nitriles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 2 | 4 | 6 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 4 | 6 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 6 | 6 |
| 2014 | 2 | 10 | 12 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 5 | 7 |
| 2017 | 3 | 6 | 9 |
| 2018 | 3 | 4 | 7 |
| 2019 | 0 | 6 | 6 |
| 2020 | 2 | 5 | 7 |
| 2021 | 4 | 9 | 13 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 9 | 10 |
| 2024 | 1 | 4 | 5 |
| 2025 | 0 | 2 | 2 |
| 2026 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitriles" by people in Profiles.
-
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium. Gynecol Oncol. 2026 Aug; 211:171-177.
-
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. Clin Cancer Res. 2026 May 15; 32(10):1973-1982.
-
Ruxolitinib and heart failure outcomes among patients with myelofibrosis. Leuk Lymphoma. 2026 May; 67(6):1335-1342.
-
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol. 2026 May; 89(5):396-403.
-
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis. Adv Ther. 2026 03; 43(3):1016-1033.
-
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer. Clin Transl Sci. 2025 12; 18(12):e70425.
-
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e258751.
-
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 06; 13(12):e7334.
-
Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2024 04 02; 23(4):552-563.